Medications for Lymphoma Mantlecell

9 results

  • Bortezomib (bortezomib)

    (Bortezomib)
    Novadoz Pharmaceuticals LLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (Bortezomib)
    Accord Healthcare Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (BORTEZOMIB)
    Hospira, Inc.
    Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (bortezomib)
    Hikma Pharmaceuticals USA Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (Bortezomib)
    NorthStar RxLLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Boruzu (bortezomib)

    (Bortezomib)
    Amneal Pharmaceuticals LLC
    Usage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Lenalidomide (lenalidomide)

    (Lenalidomide)
    Biocon Pharma Inc.
    Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.

  • Lenalidomide (lenalidomide)

    (lenalidomide)
    Cipla USA Inc.
    Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.

  • Lenalidomide (lenalidomide)

    (Lenalidomide)
    Teva Pharmaceuticals Inc
    Usage: Lenalidomide is indicated for adult patients with multiple myeloma in combination with dexamethasone, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes with a deletion 5q abnormality, and relapsed or progressed mantle cell lymphoma after two prior therapies. Not recommended for CLL.